Affymetrix to Launch Next-Gen Cytogenetics Array in Q3, Plans FDA Submission

Affymetrix expects CytoScan HD to "set performance standards" in the cytogenetics research market, and believes that the new chip will have the "broadest degree of coverage for constitutional and cancer applications."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.